Published by Josh White on 14th April 2022
(Sharecast News) - Clinical-stage pharmaceutical company Poolbeg Pharma reported on the strengthening of its intellectual property (IP) for its 'POLB 002' asset on Thursday - a first-in-class, intranasally-administered RNA-based immunotherapy for respiratory virus infections.
URL: http://www.digitallook.com/dl/news/story/32608632/...